Article info
PDFLetter
Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study
- Correspondence to Dr Ruth Wittoek, Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, Ghent B-9000, Belgium; ruth.wittoek{at}UGent.be
Citation
Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study
Publication history
- Received August 12, 2016
- Revised November 18, 2016
- Accepted November 20, 2016
- First published December 8, 2016.
Online issue publication
May 10, 2023
Article Versions
- Previous version (12 January 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/